Baillie Gifford & Co’s Lyell Immunopharma LYEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-7,097
Closed -$196K 279
2024
Q3
$196K Sell
7,097
-18,903
-73% -$555K ﹤0.01% 264
2024
Q2
$754K Sell
26,000
-6,808
-21% -$324K ﹤0.01% 260
2024
Q1
$1.46M Sell
32,808
-1,736
-5% -$74.3K ﹤0.01% 252
2023
Q4
$1.34M Sell
34,544
-2,088
-6% -$75.2K ﹤0.01% 256
2023
Q3
$1.08M Sell
36,632
-1,434
-4% -$68.1K ﹤0.01% 263
2023
Q2
$2.42M Hold
38,066
﹤0.01% 251
2023
Q1
$1.8M Hold
38,066
﹤0.01% 256
2022
Q4
$2.64M Buy
38,066
+311
+0.8% +$30.9K ﹤0.01% 257
2022
Q3
$5.54M Buy
37,755
+2,372
+7% +$321K 0.01% 236
2022
Q2
$4.62M Sell
35,383
-3,854
-10% -$394K ﹤0.01% 237
2022
Q1
$3.96M Buy
39,237
+3,068
+8% +$372K ﹤0.01% 256
2021
Q4
$5.6M Buy
36,169
+14,795
+69% +$3.3M ﹤0.01% 260
2021
Q3
$6.33M Buy
21,374
+8,433
+65% +$2.53M ﹤0.01% 256
2021
Q2
$4.2M Buy
+12,941
New +$4.24M ﹤0.01% 260

Other funds holding LYEL